Magnesium-Diapsoral 4mmol

Magnesium sulfate heptahydrate, the active ingredient in Magnesium-Diapsoral 4mmol, is an electrolyte solution presented as a 4mmol injectable preparation for intramuscular and intravenous use. It helps restore magnesium levels in patients with deficiency or specific clinical conditions requiring magnesium supplementation.

GNH USA supplies Magnesium-Diapsoral 4mmol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Magnesium sulfate is employed in several clinical situations that involve magnesium deficiency or the need for magnesium’s physiological effects. - Severe hypomagnesemia: restores serum magnesium concentrations. - Preeclampsia/eclampsia: prevents and treats seizures in pregnant women. - Torsades de pointes: stabilises cardiac rhythm in polymorphic ventricular tachycardia. - Tocolysis (preterm labor): relaxes uterine smooth muscle to delay premature contractions.

Adverse reactions may occur with magnesium sulfate administration.

Common Side Effects: - Flushing or warmth at the injection site - Nausea or vomiting - Headache - Hypotension - Sweating - Dizziness

Serious or Rare Side Effects: - Respiratory depression or arrest - Severe hypotension or cardiovascular collapse - Hypermagnesemia leading to cardiac arrhythmias - Neuromuscular blockade causing muscle weakness - Anaphylactic or severe allergic reactions - Cardiac arrest

Magnesium sulfate should be used with careful clinical assessment and monitoring. - Renal impairment: monitor serum magnesium and adjust dose. - Cardiac disease: use cautiously due to potential hypotensive effects. - Pregnancy: assess risk‑benefit, especially in preeclampsia management. - Concomitant neuromuscular blockers: monitor for enhanced paralysis. - Electrolyte imbalance: correct concurrent abnormalities before use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Magnesium sulfate can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Calcium channel blockers: additive hypotensive effect. - Neuromuscular blocking agents: prolonged paralysis. - Other magnesium‑containing products: risk of hypermagnesemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal magnesium loss. - ACE inhibitors or ARBs: alter renal handling of magnesium. - Aminoglycoside antibiotics: may potentiate neuromuscular blockade.